Next-Generation Therapeutic Bacteriocins for Targeted Biofilm Disruption

A novel system for treating bacterial infections by utilizing bacteriocins with advanced receptor-mediated translocation domains and cargo domains to selectively target and disrupt biofilm formation in Gram-negative bacteria, thereby preventing antibiotic resistance.

The original patent disclosed therapeutic bacteriocins for reducing microbial growth. However, the limitations of these bacteriocins include their inability to selectively target specific bacterial species and their potential to contribute to antibiotic resistance. The new inventive concept addresses these limitations by envisioning a next-generation bacteriocin system that can target and disrupt biofilm formation in Gram-negative bacteria, thereby preventing antibiotic resistance.

The new inventive concept comprises a bacteriocin with a receptor-mediated translocation domain and a cargo domain that can selectively target and disrupt biofilm formation in Gram-negative bacteria. The receptor-mediated translocation domain recognizes specific receptors on the surface of Gram-negative bacteria, allowing the bacteriocin to target these bacteria with high specificity. The cargo domain then disrupts biofilm formation, preventing the development of antibiotic resistance. This system can be administered as a therapeutic composition, used as a biosensor to detect bacterial infections, or modulate the gut microbiome to promote a healthy balance of gut microbiota.

The new claims introduce the concept of selectively targeting and disrupting biofilm formation in Gram-negative bacteria using advanced receptor-mediated translocation domains and cargo domains. This is a significant departure from the original patent, which did not address biofilm formation or antibiotic resistance. The new inventive concept's ability to prevent antibiotic resistance and target specific bacterial species is a non-obvious improvement over the original patent.

Alternative embodiments of the inventive concept could include the use of different receptor-mediated translocation domains or cargo domains to target different bacterial species or disrupt different cellular pathways. Variations could also include the use of the bacteriocin system in combination with other antimicrobial agents or as part of a personalized medicine approach.

The new inventive concept has significant commercial potential in the treatment of bacterial infections, particularly those caused by antibiotic-resistant Gram-negative bacteria. The market for antimicrobial therapies is growing rapidly, and the ability to prevent antibiotic resistance and target specific bacterial species could revolutionize the treatment of bacterial infections.